source
- Grace Science says FDA bottleneck jeopardizes rare disease therapyGrace Science appeared to be one of the few companies fighting ultra-rare diseases whose gene therapy candidate might make it across the finish line. Co-founded by Nobel laureate Carolyn Bertozzi,…Endpoints · 1mo ago↗ source
- Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesTrodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.BioPharma Dive · 1mo ago↗ source
- A different approach to lowering healthcare costsLast month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...